This is the authors' abstract. We don't add key points for this paper.
The U.S. has made enormous progress in the care of people with sickle cell disease (SCD) over the past 4 decades. Even in the absence of the discovery of new medications, median survival has increased dramatically from death typically occurring during early childhood in the 1970s to survival now in the mid-50s for individuals with hemoglobin SS and mid-60s for individuals with hemoglobin SC disease.1,2 This progress has been made possible through universal newborn screening, the effective use of penicillin, and more recently of hydroxyurea, careful monitoring, and the provision of supportive care.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Homer et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: